
Izonsteride
CAS No. 176975-26-1
Izonsteride( —— )
Catalog No. M34293 CAS No. 176975-26-1
Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 243 | Get Quote |
![]() ![]() |
5MG | 380 | Get Quote |
![]() ![]() |
10MG | 570 | Get Quote |
![]() ![]() |
25MG | 882 | Get Quote |
![]() ![]() |
50MG | 1178 | Get Quote |
![]() ![]() |
100MG | 1575 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameIzonsteride
-
NoteResearch use only, not for human use.
-
Brief DescriptionIzonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.
-
DescriptionIzonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is used in the treatment of oncology and genitourinary disorders, and may be used in the study of prostate cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetReductase
-
RecptorReductase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number176975-26-1
-
Formula Weight422.61
-
Molecular FormulaC24H26N2OS2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12C=3C(=CC(SC4=NC=5C(S4)=CC=CC5CC)=CC3)CC[C@]1(N(C)C(=O)CC2)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
Difubenzuron
Diflubenzuron is a benzoyl-urea insecticide, found to be a potent inhibitor of melanosome synthesis in mouse melanoma cells.
-
BYAKANGELICIN(b)
BYAKANGELICINa main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitorand is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.
-
Ponalrestat
ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice